Member Info for WeTookPelham

Don't forget Phil L'H we know is confirmed as a panel member for the opening panel at Anglo Nordic, April 3rd.

Well...that was (relatively) unusual?

The "Panel: What's Next in Immunology" seems to a prime panel slot straight after the keynot opening?

Also very interesting video by the Merck person sharing the panel with Phil L'Huillier:

https://www.youtube.com/watch?v=k6Cs8khY0xk

Https://www.anglonordiclifescience.com/

"WHY ATTEND?

On 3 April, 2025, over 400 delegates from leading and upcoming drug discovery and technology companies from the UK, Nordic and many other European regions, plus investment firms throughout Europe, will get together in London for the 21st Annual Anglonordic Life Science Conference.

The Reception, our must-attend networking event, takes place the evening before at the London Institute for Healthcare Engineering.

The Conference will be attended by high quality investors, featuring on-point panel discussions around European investment and technologies, and 36 funding pitches presented by cutting-edge biomedical and healthcare startups.

1:1 partnering takes place throughout the day."

https://anglonordic2025.meeting-mojo.com/schedule#/track/0

09:15 - 10:00

Biotech Room 1

Panel: What's Next in Immunology

Chair: ELEANOR MALONE

Editor-in-Chief, Commercial Insights

Citeline

Panel:

MARK BODMER

CEO

Nucleome Therapeutics

MARTA HELENA LESKO

Head of Global Business Development Neurology & Immunology

Merck KGaA

PHIL L'HUILLIER

CEO

Scancell

MARINA UDIER

CEO

Nouscom AG

If Google search for the last 24 hours is to be believed then there appears to be an update on the Macmillan site, but it's a nightmare to navigate so can't tell.

...at the close and after the bell.

@Jb1 - K.V.?

Many thanks VanVan, very interesting and useful.

Although is it somewhat of a shame someone had to email to get that kind of info?

"...the fact that only the CEO and CFO went to JP Morgan spoke volumes for 1."

I agree with this wholeheartedly, and I don't think the significance of this has been noted, in particular the CEO being there. I personally feel they didn't fly over to JPM conference to network or to schmooze, but for a particular reason i.e. some form of deal making. IMO.

Perfect summation moonparty, IMO.

Well someone clearly sees this as a good price to buy a big chunk.

Someone not a fan of the poster?

Joking aside, having relatively low volume shows it doesn't take much to bring it down?

But why sell in multiples of 5000 shares, too much of a coincidence it's different sellers selling the same amount of shares at the same time?

On LinkedIn they were, and now assume have filled a role for clinical trial assistant. Closing date was 10th.

Based in Oxford, interestingly?

Keep fighting 💪

"...Perhaps the news next week may turn out to be a bigger game-changer than the low-key announcement implied?"

I know Scancell are notoriously inconsistent when they RNS conferences/presentations, but I did notice they RNS the conference next week, but they didn't for the JP Morgan one in January when the CEO was in attendance. Arguably JP Morgan is the more prestigious event?

Ah I missed that troajan has posted the proactive summary of today's RNS, but yes that also says "new findings":

"...Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) will present new findings from its ongoing phase II clinical trial at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference in Los Angeles from 23-26 February.

The data will highlight how its experimental melanoma vaccine, SCIB1, is working in combination with two widely used cancer drugs, nivolumab and ipilimumab."

Can't see your post crackpot as you're on my filtered, but as night follows day, your appearance fills me with glee.

The "crackin inverse indicator" is almost perfect 😉

Linkedin post:

"....Next week, Joe Chadwick, Translational Research Scientist at Scancell, will be on the ground in Los Angeles, US to present a poster at AACR IO. Held from 23-26 February and hosted by the American Association for Cancer Research, this event will showcase the latest discoveries and innovations driving forward progress in cancer #immunology, including #CancerVaccines.

Joseph’s presentation, ‘A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab induces functional CD4 and CD8 T cell responses in patients with advanced unresectable melanoma,’ will showcase new data from our Phase 2 SCOPE study of lead Immunobody® cancer vaccine candidate SCIB1 in advanced #melanoma. Join him from 1:45 PM – 4:45 PM PT on 25 February to learn more"

"...Will showcase NEW data"?

Https://www.nature.com/articles/d43747-023-00124-x

Check out the "stage signed" column.

Typo's:

"EE's 9:05* post"

"No one can come up with an decent argument against* this IMO"